CAR T-cells

3:05
Predicting MM response to cellular and immunotherapies
Paola Neri
2:25
Increase in cancer patient transfers to the ICU: what does it come down to?
Michael von Bergwelt
2:33
EuroCARTForce: a platform for progress
Michael von Bergwelt
1:14
Preparing the critical care workforce for CAR-T
Michael von Bergwelt
1:10
ICU admission in CAR-T treated patients
Élie Azoulay
1:15
How could CAR-T affect transplantation in R/R lymphomas?
Robin Sanderson
2:07
CAR-T side effects: CRS, neutropenic fever & MAS/HLH
Sandrine Valade
2:12
Improving management of adverse events in CAR-T patients
Élie Azoulay
2:51
CAR T-cell therapy: CRS and adverse effects
Michel Sadelain
1:04
What to expect at the upcoming EMBT-EHA CAR-T Meeting
Orla Stewart
9:35
Treatment-changing advancements in CLL: BTK, BCL-2, CD20 & CAR T-cells
Kanti Rai
1:07
Sequential therapy and drug resistance in CLL in the era of targeted agents
Stephan Stilgenbauer
2:11
Cellular therapies in CLL: from transplant to CAR T-cells?
Jennifer Brown
3:00
CAR T-cells for multiple myeloma: update & what’s in store for ASH 2018
Jesús Berdeja
2:42
Toxicity profile for CAR T-cells in multiple myeloma
Jesús Berdeja
11:58
iwNHL day 2 highlights: bridging the gap to CAR T-cell therapy & precision medicine
Anas Younes et al.
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals